netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Atezolizumab found 13 matches
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Atezolizumab Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
 
Non Formulary BNF Category
  Cytotoxic Drug Atezolizumab Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (June 2021): Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) (08.01.05)
link in drug section NICE TA1047:Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) (08.01.05)
link in drug section NICE TA1071: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (08.01.05)
link in drug section NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (08.01.05)
link in drug section NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (08.01.05)
link in drug section NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (08.01.05)
link in drug section NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (08.01.05)
link in drug section NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (08.01.05)
link in drug section NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (08.01.05)


 
netFormulary